Abstract Number: 1165 • 2013 ACR/ARHP Annual Meeting
Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behςet’s Syndrome (BS)
Background/Purpose: Behcet's syndrome (BS) exhibits features of both innate and acquired immunity. Oral ulceration is the cardinal lesion which usually precedes other manifestations. Despite the…Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…Abstract Number: 893 • 2013 ACR/ARHP Annual Meeting
Association Between Human Leukocyte Antigen-B’s Amino Acid Variation and Disease-Susceptibility To Takayasu’s Arteritis
Background/Purpose: HLA-B52 and HLA-B51 are frequently seen in Asian population and are almost identical except two amino acid residues(the 63rd and 67th), but HLA-B52 is…Abstract Number: 2624 • 2013 ACR/ARHP Annual Meeting
Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet’s Disease
Background/Purpose: One of the major causes of mortality and morbidity in Behcet’s disease (BD), especially in young males of Mediterranean origin, is vascular involvement. A…Abstract Number: 2625 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients
Background/Purpose: Several situations can be observed in patients undergoing biologic therapy in uveitis associated to Behçet´s syndrome (BS): a) Patients are switched to another therapy…Abstract Number: 2627 • 2013 ACR/ARHP Annual Meeting
Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease
Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet's…Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…Abstract Number: 181 • 2012 ACR/ARHP Annual Meeting
Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Background/Purpose: Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment…Abstract Number: 183 • 2012 ACR/ARHP Annual Meeting
A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome
Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and…Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…Abstract Number: 2385 • 2012 ACR/ARHP Annual Meeting
Prognostic Impact of HLA-B*51 and HLA–A*26:01 On Ocular Behcet’s Disease
Background/Purpose: To investigate the prognostic implication of HLA-B*51 and HLA-A*26:01on visual outcome in Korean Behcet’s disease (BD) patients with uveitis. Methods: Seventy-seven Korean BD patients…Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…Abstract Number: 2394 • 2012 ACR/ARHP Annual Meeting
Fibromyalgia in Behçet’s Disease Is Associated with Disease Activity
Background/Purpose: Studies on the relationship between Fibromyalgia (FM), a generalized pain disorder with up to 2% prevelance and Behcet’s Disease (BD), a systemic, inflammatory vasculitis,…Abstract Number: 2369 • 2012 ACR/ARHP Annual Meeting
Aspects of Innate Immunity in Behçet´s Disease: A Model of Autoinflammatory Disease?
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis of unknown etiopathogenesis. Increased neutrophil activation has been previously shown in BD patients and it is unclear…
ACR Meeting Abstracts